Company news

Arvinas, Inc. news in 2025

Arvinas, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

December 5, 2025

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

November 25, 2025

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

November 23, 2025

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 4, 2025

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

November 2, 2025

Arvinas to Participate in Upcoming Investor Conferences

November 2, 2025

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

October 28, 2025

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 23, 2025

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 21, 2025

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

October 19, 2025

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

October 12, 2025

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

October 4, 2025

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

September 30, 2025

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

September 16, 2025

Cascade Prodrug Inc. Appoints Industry Veterans Manuel (Manny) Litchman and Andres Gutierrez to Board of Directors

August 28, 2025

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

August 7, 2025

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 5, 2025

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

July 29, 2025

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

July 8, 2025

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

June 12, 2025

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

June 5, 2025

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

June 4, 2025

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

May 30, 2025

Arvinas to Present at Jefferies Global Healthcare Conference

May 29, 2025

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

April 30, 2025

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

April 27, 2025

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

April 27, 2025

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

April 22, 2025

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

April 20, 2025

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

April 3, 2025

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

March 26, 2025

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

March 10, 2025

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

February 10, 2025

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

February 2, 2025

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

January 9, 2025

Calls in 2025

Decks in 2025